WO2013144977A3 - An improved process for the preparation of etoricoxib - Google Patents

An improved process for the preparation of etoricoxib Download PDF

Info

Publication number
WO2013144977A3
WO2013144977A3 PCT/IN2013/000187 IN2013000187W WO2013144977A3 WO 2013144977 A3 WO2013144977 A3 WO 2013144977A3 IN 2013000187 W IN2013000187 W IN 2013000187W WO 2013144977 A3 WO2013144977 A3 WO 2013144977A3
Authority
WO
WIPO (PCT)
Prior art keywords
etoricoxib
preparation
improved process
formula
acid
Prior art date
Application number
PCT/IN2013/000187
Other languages
French (fr)
Other versions
WO2013144977A2 (en
Inventor
Siva Prasad Reddy DORASALA
Raja Mahender Reddy NALLA
Purandhar Koilkonda
Shankar Rama
Jagan Mohana Chary TUMMANEPALLY
Original Assignee
Mylan Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd. filed Critical Mylan Laboratories Ltd.
Priority to EP13731500.8A priority Critical patent/EP2831045A2/en
Publication of WO2013144977A2 publication Critical patent/WO2013144977A2/en
Publication of WO2013144977A3 publication Critical patent/WO2013144977A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an improved process for the preparation of Etoricoxib by reacting ketosulfone of formula-ll with vinamidinium salt of formula-Ill in the presence of an acid, followed by conversion to an acid addition salt and finally desaltifying to get Etoricoxib of formula-l.
PCT/IN2013/000187 2012-03-30 2013-03-20 An improved process for the preparation of etoricoxib WO2013144977A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13731500.8A EP2831045A2 (en) 2012-03-30 2013-03-20 An improved process for the preparation of etoricoxib

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1261/CHE/2012 2012-03-30
IN1261CH2012 2012-03-30
IN2794/CHE/2012 2012-07-10
IN2794CH2012 2012-07-10

Publications (2)

Publication Number Publication Date
WO2013144977A2 WO2013144977A2 (en) 2013-10-03
WO2013144977A3 true WO2013144977A3 (en) 2013-12-12

Family

ID=48699212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000187 WO2013144977A2 (en) 2012-03-30 2013-03-20 An improved process for the preparation of etoricoxib

Country Status (2)

Country Link
EP (1) EP2831045A2 (en)
WO (1) WO2013144977A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110143915A (en) * 2019-06-03 2019-08-20 蚌埠学院 A kind of novel crystal forms and preparation method of Etoricoxib and p-methyl benzenesulfonic acid forming salt

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US20020147221A1 (en) * 2000-05-26 2002-10-10 Crocker Loius S. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
WO2011158250A1 (en) * 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
WO2012004677A1 (en) * 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) * 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EA002975B1 (en) 1998-04-24 2002-12-26 Мерк Энд Ко., Инк. Process for synthesizing cyclooxygenase-2 inhibitors
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US20020147221A1 (en) * 2000-05-26 2002-10-10 Crocker Loius S. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
WO2011158250A1 (en) * 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
WO2012004677A1 (en) * 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) * 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib

Also Published As

Publication number Publication date
EP2831045A2 (en) 2015-02-04
WO2013144977A2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IL257841A (en) Preparation, uses and solid forms of obeticholic acid
EP3778606A3 (en) Condensed imidazolylimidazoles as antiviral compounds
EP2864306B8 (en) Purifying crude furan 2,5-dicarboxylic acid by hydrogenation
WO2014083438A3 (en) Nitric oxide increasing nutritional supplements and methods
WO2013021279A3 (en) Highly galactosylated antibodies
IN2015KN00262A (en)
WO2013012921A3 (en) Nucleic acid aptamers
WO2014060099A3 (en) Microspheres
HUE049168T2 (en) Microorganism able to produce l-amino acid, and method for producing l-amino acid by using same
IN2015KN00323A (en)
EP2542234A4 (en) Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
WO2013096603A3 (en) Cellobiohydrolase variants and polynucleotides encoding same
WO2013128294A3 (en) Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
WO2014057498A3 (en) Process for the preparation of cobicistat intermediates
MX362689B (en) Method for producing 3,5-bis(fluoroalkyl)-pyrazol-4-carboxylic acid derivatives and 3,5-bis(fluoroalkyl)-pyrazoles.
IN2014DN07691A (en)
WO2013188432A3 (en) Asymmetric catalysts
WO2014091167A3 (en) Cyclopropylboronic compounds, method for preparing same and use thereof
HK1205692A1 (en) Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance ---
WO2013168176A3 (en) Process for preparation of fosaprepitant and salt thereof
WO2013152860A3 (en) Improved antibody light chains
WO2014091386A3 (en) An improved process for preparation of minodronic acid
EP2840088A4 (en) Method for preparing 5,6,4'-trihydroxyflavone-7-0-d-glucuronic acid
EP2805956A4 (en) Gambogenic acid derivatives, preparation method and application thereof
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13731500

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2013731500

Country of ref document: EP